All In Biotech

Drug Trial Radar · NCT04909164

The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients

The Pragmatic Clinical Trial to Elucidate Optimal Target Population of Immunotherapy From Real-world Lung Cancer Patients

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,519

Actual

Start

Jun 15, 2021

Primary completion

Dec 31, 2025

Study completion Jul 30, 2026

Sponsor

Lead sponsor
Myung-Ju AhnAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Evidence-Based Healthcare Collaborating Agency
First posted
Jun 1, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The pragmatic clinical trial to elucidate optimal target population of immunotherapy from real-world lung cancer patients

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • Immunnotherapy groupDrug

    Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: Up to 3 years
  2. Overall-survivalTime frame: Up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.